Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar ExtremesTracker (27.37) Submitted: 12/7/2010 6:11:40 PM : Outperform Start Price: $2.45 IDRA Score: -66.60

picks source: zzlangerhans
as of 12/7/2010, these were the 5 most underperformed designated "top picks" by zz. these are the 5 picks (out 7 top picks):
alny,idra,rtix,biod,bdsi
No due diligence performed, these are hail marys that atleast a couple may possibly be insane multi baggers potentially
Very risky.

Featured Broker Partners


Advertisement